AJ-2615, a dual calcium antagonist and alpha1-adrenoceptor blocker: implications for CABG patients Sep. 18, 2001
Proof of principle demonstrated in phase II studies for novel cardiology candidate therapeutic Sep. 18, 2001
RSS